Industry Outlook
The plasma fractionation market is set to reach from US$ 18,099.5 Mn in 2017 to US$ 33,386.6 Mn by 2026 at a compound annual growth rate (CAGR) of 7.1% during the forecast period from 2018 to 2026. Plasma fractionation is utilized for achieving large quantities of purified protein from human plasma. Researchers have been focusing diligently in understanding the role and significance of plasma derived proteins in treating chronic ailments and autoimmune diseases. Increasing demand for biologics and increasing healthcare expenditure for drug development activities together drive the plasma fractionation market growth.
Get a sample copy for more information
Rising prevalence of autoimmune disorders and technical innovation in deriving highly purified proteins from human plasma drive the immunoglobulin market growth
Immunoglobulin are reigning the product segment for plasma fractionation market. Technical innovations in deriving highly purified proteins from human plasma and rising prevalence of autoimmune disorders drive the immunoglobulin market growth. They are primarily of 5 classes (D,G,M,A,E) and several subclasses, responsible for consolidating the immune system. Albumin is gaining huge attention among researchers owing to its drug binding properties and its effective use as drug formulating agent, medical device coating, surgery sealants and vaccine ingredient.
Get a sample copy for more information
Increasing morbidity and lack of effective biological treatment drive the neurology applications market growth
According to World Health Organization (WHO), approximately 450 million people are reported annually to be suffering with mental illness. Neurology is dominating the application segment for plasma fractionation market. The chief attributes governing its market growth are increasing morbidity and lack of effective biological treatment for neurological disorders. Recently newer antibodies have been developed to hinder the process of protein clusters misfolding which causes Alzheimer’s and Parkinson’s disease. Immunology application will be the fastest growing segment in the near future owing to the significant rise in immunocompromised patients and technological advancement in the development of immunoglobulin to counteract disease manifestations associated with immunosuppression.
Get a sample copy for more information
Increasing number of patients suffering with chronic disease and presence of state of the art healthcare infrastructure drive the market growth in North America
North America is the supreme leader in global plasma fractionation market representing 38% share. The dominance is attributed to major factors such as increasing number of patients suffering with chronic diseases and presence of state of the art healthcare infrastructure. As per the statistics provided by Center for Disease Control and Prevention (CDC), 1 in every 6 American is living with chronic disease. Europe holds 25% market share owing to the existence of key players such as Biotest AG, Sanquin, Octapharma AG, Grifols, S.A. and supportive regulatory environment provided by the European Medical Agency (EMA). Asia Pacific is responsible for 17% share and will showcase impressive growth during the forecast period on account of rise in per capital income and affordable reimbursement scenario for plasma fractionation products utilized during treatment of chronic ailments.
Historical & Forecast Period
This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2018 to 2026.
Report Scope by Segments
The market segmentation comprises of by product, by application and geography.
| ATTRIBUTE |
DETAILS |
| Research Period |
2017-2027 |
| Base Year |
2018 |
| Forecast Period |
2019-2027 |
| Historical Year |
2017 |
| Unit |
USD Million |
| Segmentation |
By Product (2016–2026; US$ Mn)
• Coagulation Factor Concentrates
• Immunoglobulin
• Albumin
• Protease Inhibitors
• Others
|
|
By Application (2016–2026; US$ Mn)
• Neurology
• Immunology
• Hematology
• Critical Care
• Others
|
|
Geography Segment (2016–2026; US$ Mn)
• North America (U.S., Canada)
• Europe (U.K., Germany, Rest of Europe)
• Asia Pacific (China, Japan, Rest of Asia Pacific)
• Latin America (Brazil, Mexico, Rest of Latin America)
• Middle East and Africa (GCC, Rest of MEA)
|
Biopharmaceuticals actively engaged in providing plasma fractionation products are Baxter International, Inc., Biotest AG., CSL Limited, Grifols, S.A., Green Cross Corporation, Japan Blood Products Organization, Kedrion Biopharma, Inc., Octapharma AG., Sanquin and Shire, Plc.
Key questions answered in this report
- What are the latest inorganic and organic market growth strategies adopted in plasma fractionation market?
- Which biopharmaceutical companies are providing plasma fractionated products for treating chronic ailment?
- What are the latest technical innovation associated with human plasma protein purification?
- What are the clinical use of immunoglobulin?
- What is the prevalence rate of neurological disorders and its treatment by using antibodies?
- What is the plasma fractionation market growth in developing nation such as Asia Pacific, Latin America and Middle East & Africa?
